The UK and US have hammered out a significant trade agreement that will guarantee no levies on UK pharmaceutical shipments going into the US market.
The Terms of the Accord
Under the terms of the agreement, the UK has agreed to boost expenditure on pharmaceuticals through the NHS. This pledge guarantees that import taxes on these crucial goods will be held at nothing for a duration of three years.
This deal is in response to previous threats to hike import taxes on patented drug products, with potential rates discussed as high as double the cost.
"This deal with the UK bolsters the global environment for innovative medicines and introduces long-overdue equity to American-British drug exports," a release noted.
Commercial Impact
Pharmaceuticals represent one of the UK's largest exports to the United States, which is by far the primary market for major companies like GSK and AstraZeneca.
Statistics indicate that in the one-year period prior to the third quarter, the UK sold medicines worth £11.1bn to the US. This amount made up 17.4% of all goods exports in that period.
"This guarantee safeguards employment, boosts funding and sets the stage for the UK to emerge as a worldwide center for life sciences," a minister commented.
Specific British Pledges
The pact includes several specific commitments from the UK:
- Price Threshold Increase: The UK will increase the price threshold at which it judges new medicines to be prohibitively costly by 25%.
- Increased NHS Spending: There is a aim to raise total public funding on medicines from 0.3% of GDP to 0.6% over the coming ten years.
- Payback Limit: The percentage manufacturers must pay back to the NHS to prevent overspending will be restricted at fifteen percent. Last year, rebates topped 20%.
Recent Tensions
This agreement follows a protracted row between the pharmaceutical industry and the ministers over spending levels and regulatory access.
The disagreement were heightened by arguments that American patients were paying a premium for the equivalent treatments than consumers in the Britain and the EU.
Recently, several significant pharmaceutical investments in the UK have been delayed or cancelled, while major investments have been directed toward US facilities.
A senior figure stated that the NHS had to invest a greater share on medicines, noting that its budget allocation on drugs had decreased as a proportion of its total funding over the past decade.
